MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

148.41B

Vuru Grade

55.06/100

Current Price

$52.69
-1.16 (-2.15%)

Growth Price

$34.71
Overvalued by 34.13%

Stability Price

$20.05
Overvalued by 61.95%

Company Metrics

  • P/E 15.39
  • P/S 3.77
  • P/B 3.27
  • EPS 3.42
  • Cash ROIC 12.10%
  • Cash Ratio 0.84
  • Dividend 1.8 / 3.26%
  • Avg. Vol. 10.13M
  • Shares 2.82B
  • Market Cap. 148.41B

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Merck andamp; Co., Inc. Top-Selling Drug Put At Risk By FDA Warning
Bidness ETC - Aug 31, 2015
Merck & Co., Inc. (NYSE:MRK) has seen its overall sales drop since FY11 as it has faced increased generic as well as biosimilar competition for some of its best-selling drugs.
FDA warns of severe joint pain risk with DPP-4 diabetes drugs - Fox News
Large Inflow of Money Witnessed in Merck & Company, Inc.
Money Flow Index - 21 hours ago
Merck & Company, Inc. (NYSE:MRK) dropped slightly amid mild profit booking and the last known price was $53.85 per share.
Merck & Co. Assigned "AA" Credit Rating by Morningstar (MRK) - WKRB News
Merck & Company, Inc. Analyst Rating Update
News Watch International - Sep 1, 2015
As many as 14 brokerage firms have rated Merck & Company, Inc. (NYSE:MRK) at 2. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term.
Merck & Co. Inc. (MRK) Closes 2.45% Down on the Day for September 01
Equities.com - 9 hours ago
Dow Jones component Merck & Co. Inc. (MRK) saw its stock move -2.45% to $52.53, representing a per-share move of $1.32, on volume of 15.67 million shares for Tuesday.
Organovo CEO Keith Murphy: 'People Are Missing The Forest For The Trees'
Benzinga - 11 hours ago
BZ: How do you see the collaborations with Merck & Co., Inc. (NYSE: MRK), L'Oréal and the Yale School of Medicine helping overall?
Why Wayfair Inc. (W), Alibaba Group Holding Ltd (BABA) and Merck &Co., Inc ...
Investorplace.com - Aug 31, 2015
All told, crude oil gained more than 7%, while the S&P 500 Index lost 0.84% of its value. It was much worse for Merck & Co., Inc. (NYSE:MRK), Wayfair Inc. (NYSE:W) and Alibaba Group Holding Ltd (NYSE:BABA) shareholders, however. Here's why.
Worth Watching Stocks - Micron Technology, Inc. (NASDAQ:MU) Merck & Co. Inc ...
wsnewspublishers - Aug 31, 2015
On Friday, Shares of Micron Technology, Inc. (NASDAQ:MU), gained 1.85% to $15.96, after the chairman of China's Tsinghua Unigroup came to the U.S.
Company Shares of Merck & Company, Inc. (NYSE:MRK) Drops by -0.72%
Insider Trading Report - Aug 31, 2015
Merck & Company, Inc. (NYSE:MRK) has lost 0.72% during the past week and dropped 6.09% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 1.61%.
News Recap - Ford Motor Co. (NYSE:F) Merck & Co. Inc. (NYSE:MRK) Immunomedics ... - wsnewspublishers
Drug Manufacturers Not to Miss - Merck & Co. Inc. (NYSE:MRK), AbbVie Inc ...
Wall Street Observer - Aug 31, 2015
Merck & Co. Inc. (NYSE:MRK) with a market cap of 155.96B and a dividend of 3.25% closed the day at 55.37. Merck & Co. Inc. is currently reporting earnings per share of 3.42 and has a target price of 65.29. The company maintains a gross margin of 63.00% ...
Drug Most Active Stocks: Merck & Co. Inc. (NYSE:MRK), AbbVie Inc. (NYSE:ABBV ... - Stock Transcript
Drug Sector Highest Volumes: Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE ... - Property Mentor
Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted its ...
Inside Trade - Aug 26, 2015
Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Keytruda, an anti-PD-1 therapy, for review.